The objective of our study was to determine the maximal non-reactive concentrations for midazolam and ketamine in healthy volunteers using both prick and intradermal skin tests. Twenty-one healthy Caucasian volunteers were tested for midazolam and ketamine using more clustered concentrations (identical for both prick and intradermal tests) than those resulting from decimal dilutions. The criteria for positivity were based on dilutions of drugs that cause wheal and flare reactions in subjects without history of allergy. For the prick method, the concentrations that did not produce wheal and flare were 1 mg/ml for midazolam and 10 mg/ml for ketamine. For intradermal tests, using serial dilutions, we found that the highest concentration for which the subjects did not pass the positivity criteria was 0.25 mg/ml for both drugs.
Patients undergoing general or local anaesthesia are exposed to numerous drugs and other substances in a short period of time (e.g. neuromuscular blocking agents, hypnotics, opioids, antibiotics, local anaesthetics, blood products, latex, disinfectants). Administration of these substances can produce allergic reactions (immune mediated) and pseudo-allergic reactions (non-immune mediated). Anaphylactic reactions occur in one in 5000 to 20,000 anaesthetic procedures 1, 2 . The types of allergic anaphylaxis are subdivided into IgE-mediated and non-IgE-mediated reactions 3 . In the subset of IgEmediated reactions, prick and intradermal skin tests represent an important diagnostic tool. It is well established that intradermal tests are likely to give false-positive results more often than prick tests, especially for high drug concentrations 4 . Most of the published reports have used serial decimal dilutions. These may not be accurate enough to define the highest concentration associated with the lack of a false-positive skin test.
Diagnosis of anaphylaxis during anaesthesia is not always straightforward. Ideally, the diagnosis should rest upon several confirmatory tests rather than a single one. In the event of discrepancies between different tests, an alternative compound should be tested 5 . When a patient with a previous allergy to anaesthetic drugs is investigated in an anaesthesia allergy centre, skin tests are performed for all the substances used in order to identify the culprit agent. One commonly used anaesthetic agent is midazolam. Thus midazolam is frequently tested, even though the incidence of midazolam allergy is low (0.57 to 0.62% of anaesthetic anaphylaxis) 6, 7 . In daily practice, midazolam is also tested as an alternative compound. Moreover, midazolam and other compounds are tested for research purposes (e.g. prevalence of positive skin tests to anaesthetic drugs) 8 . In our centre, using the concentration recommended by current guidelines for midazolam (1 mg/ml for prick tests and 0.5 mg/ml for intradermal tests) 5,9 for 18 months, we observed a large number of positive intradermal tests (21% of 96 patients). Only one of the positive intradermal tests was confirmed by basophil activation tests. All prick tests performed for midazolam were negative. In a previous paper we reported a series of 39 patients allergic to medication other than anaesthetic agents, who were screened preoperatively for anaesthetic drugs substances. Eleven of them (28%) met the positivity criteria for midazolam intradermal tests 10 . These high incidences for positive intradermal tests are disproportionately high compared with the incidence of anaphylactic reactions, bearing in mind that midazolam is used in a high proportion of patients who undergo surgery.
Ketamine is a popular choice for procedural sedation and analgesia 11 . The incidence of ketamine allergy is also very low (0.8% of anaesthetic anaphylaxis) 12 . Ketamine is tested in order to find the causative agent when a patient has had an anaphylactic reaction and ketamine was used among other anaesthetic drugs, as an alternative, and in clinical research. The absence of international validated non-reactive concentrations for ketamine skin tests represented a good reason to determine threshold concentrations for reading prick and intradermal tests to ketamine.
The aim of the present study was to identify the maximum concentration of midazolam and ketamine not associated with a false-positive reaction (i.e. no reaction) in non-allergic healthy volunteers: falsepositive results could be obtained in both healthy non-allergic and allergic subjects. We aimed to use more clustered concentrations than those resulting from decimal dilutions in order to compare different test concentrations to a reference standard 9, 13, 14 .
MATERIAls AND METHODs
With the approval of the Research Ethics Committee of our university hospital, the prick and intradermal skin tests were performed on healthy consenting volunteers using commercially available solutions (marketed products) of midazolam and ketamine. The maximum concentrations used in the tests did not exceed the concentration of the drug in the commercial vial. Normal saline solution (0.9%) was used for dilution. There was no osmolality change with the decrease in concentration of the dilutions. There was a minor change in the pH for midazolam dilutions (from 3.12 for 1 mg/ml to 4.62 for 0.001 mg/ml). For ketamine dilutions, the pH did not vary. The chemical analysis was performed using the gonotec Osmomat 030/050 osmometer (Berlin, germany).
For midazolam we tested Midazolam Torrex (Torrex Pharma gmbh, Vienna, Austria). The following concentrations were used for both tests: 0.001 mg/ml, 0.01 mg/ml, 0.05 mg/ml, 0.1 mg/ml, 0.25 mg/ml, 0.5 mg/ml and 1 mg/ml. Notably, one of these concentrations (0.5 mg/ml or 500 µg/ml) is recommended in the literature as the maximal concentration that does not result in a false-positive reaction for the intradermal test 9 .
For ketamine we used the marketed product Calypsol (gedeon Richter ltd, Budapest, Hungary). For both tests the following concentrations were used: 0.010 mg/ml, 0.05 mg/ml, 0.1 mg/ml, 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 5 mg/ml and 10 mg/ml. In the literature there are no validated non-reactive concentrations for skin tests to ketamine.
A total of 21 young healthy Caucasian volunteers, aged between 21 and 31 years, participated in the study. The group included 13 males (62%) and eight females (38%), none of whom were pregnant or breast-feeding. They were tested for midazolam and ketamine on two different dates with a period of seven days between testing. skin testing reactivity was normal for all subjects, with usual reaction to the 1% histamine positive control (wheals between 4 and 7 mm diameter, surrounded by erythema of 15 to 25 mm). Twenty subjects did not present any wheal or flare with the negative control (no doubling of the injection wheal using sodium chloride 0.9%). One subject was excluded due to skin hyperreactivity 9 (positive reaction to negative control test).
The skin tests were performed in conformity with international recommendations 9 and according to established testing methodology 15 . Our study was conducted in a prospective, double-blinded manner -one allergist with experience in skin testing and trained in anaesthesia allergy prepared the drug dilutions and performed the skin tests, while another allergist who did not know the testing concentrations measured the wheals. The skin tests were carried out on the anterior aspect of the forearm. For prick tests, solution drops of the different concentrations were placed and then the skin was pricked in the middle of each drop with a prick needle (stallerpointe, stallergenes, Antony, France), with no bleeding. For intradermal tests, a volume of approximately 0.02 to 0.03 ml was injected through a 29.5 gauge needle, resulting in an injection wheal of approximately 4 mm diameter.
The evaluation of skin reactivity of the tested subjects was carried out by comparison with controls: for prick tests the negative control was phenol saline glycerol (stallergenes) and the positive control was histamine 1% (stallergenes), the test area being situated 4 cm from the other test drops. For the intradermal test the negative control was a volume of normal saline solution injected into the skin to produce an initial wheal of 4 mm diameter.
The prick test reading was regarded as positive when the wheal diameter was superior to 3 mm within 20 minutes, compared to the negative control, or greater than or equal to half the positive control wheal 9 . For intradermal tests, the positivity criterion was the existence of a reading wheal (RW) of at least 8 mm diameter within 20 minutes, or the doubling of the initial injection wheal (IW): the RW/IW ratio greater than or equal to two 9 .
REsUlTs

Prick tests
During prick testing, no subject developed any wheal greater than or equal to 3 mm during the 20-minute interval, regardless of tested substance or concentration. When using midazolam, even with maximum concentration, no wheal or flare was observed. When using ketamine with maximum tested concentration (10 mg/ml), a 1.5 mm wheal was observed for two subjects and 1 mm wheal on one subject. No prick test passed positivity criteria.
Intradermal tests
For the intradermal skin tests with both midazolam and ketamine, the increase of the RW/ IW ratio is correlated with the increase of the substance concentration (Tables 1 and 2) .
We defined the maximal non-reactive reading concentration for each substance as the highest concentration at which the RW/IW ratio is less than 2 and the wheal does not double for any tested subject. Any concentration exceeding this concentration starts producing positivity for the intradermal test. These positive reactions of healthy volunteers are, in fact, false-positive reactions, by mechanisms other than allergic. For a midazolam concentration of 1 mg/ml, 19 subjects (95%) experienced a wheal of more than double in size and the RW/IW ratio was greater than or equal to 2. For the concentration of 0.5 mg/ml the ratio doubled for 50% of the subjects. For the concentration of 0.25 mg/ml the injection wheal did not double, so there were no positive tests, and the RW/IW ratio was less than 2. For the concentration of 0.1 mg/ml no test area changed and RW/IW ratio was less than or equal to 1.0 ( Table 1) .
For the intradermal skin test with ketamine we observed there was a concentration-dependent increase of RW/IW ratio. For a ketamine concentration of 1 mg/ml, the injection wheal doubled at the time of the reading for 17 subjects (85% of the group) and RW/IW ratio was greater than or equal to 2, while for a concentration of 0.5 mg/ml the doubling appeared on 20% of tested subjects. For the concentration of 0.25 mg/ml, the injection wheal did not double and RW/IW ratio was less than 2. Therefore, no test was positive, even if some increase in oedema of the wheal appeared. The RW/IW ratio was less than or equal to 1.0 for a concentration of 0.1 mg/ml or smaller ( Table 2) .
Cells in Tables 1 and 2 highlight the number of identical clinical observations. The flare around the injection wheal was also evaluated 20 minutes after the intradermal administration of the test solutions. This phenomenon was observed only at high concentrations and followed the increase of the RW/IW ratio (greater than or equal to 0.25 mg/ml midazolam and greater than or equal to 1 mg/ml ketamine).
DIsCUssION
Despite attempts to use laboratory tests such as the basophil activated test or the specific IgE test to identify the culprit drug or substance that causes perioperative anaphylaxis, skin tests remain a very important diagnostic tool in perianaesthetic allergy 5, 9 . Optimisation and validation of substance concentrations for skin tests have a great importance, especially in drug allergy diagnosis as no methods (skin tests, specific IgE-radioimmunoassay, basophil activation tests) can be referenced to absolute values and it is hard to establish which test is more valuable from case to case 16 . Any interpretation of skin test must take into account the issues of false-positives and false-negatives, which requires the definition of drug concentrations to be tested. For some substances there are strong recommendations regarding the concentrations that should be used for intradermal tests 17 . For other drugs such as midazolam or ketamine, the recommendations are based on few publications that have not been replicated.
Establishment of threshold concentrations necessary for the interpretation of skin tests in the field of drug allergy and the maximum concentrations that are not associated with a false-positive result for each substance can be realised by testing healthy volunteers. For skin testing, the criteria for false positivity are based on dilutions of drugs that do not cause wheal and flare reactions in subjects without a history of allergy 18 . There are ethical difficulties in testing large numbers of non-reactors simply to validate a test 18 . Although we performed our study testing only 20 individuals, the number of clinical observations was 140 for midazolam and 160 for ketamine. Research that evaluates skin reactivity to different drug concentrations are performed on smaller groups of tested subjects, as shown in some works on neuromuscular blocking agents 19, 20 .
Prick and intradermal skin tests are used commonly for establishing the drug responsible for anaphylactic reactions in anaesthesia. The agreement between these two techniques is 93%, without significant statistical differences 21 . Nevertheless, each technique has certain advantages. The prick test is quicker, simpler to perform, less traumatising, more specific and easier to apply to children than the intradermal test. However, the intradermal test is more sensitive and reproducible than the prick test 15 . Using both types of tests can improve predictability by 67% 21 , resulting in a higher degree of confidence for the patient. In the case of a negative or 'doubtful' prick test, it is recommended to continue the investigation with an intradermal test 15 .
Intradermal tests are prone to false-positive results when too high a concentration is used 22 . On the other hand, using too low a concentration is a source of false-negative results 23 . In the context of anaesthesia allergy, a false-positive result is less dangerous than a false-negative result 24 . The issue is to avoid both false-positive and false-negative reactions 18 . For this purpose, intradermal testing with more clustered concentrations than those resulting from decimal dilutions in the case of serial intradermal tests seems more appropriate.
Our results should be interpreted by taking the following into consideration: 1) the skin area chosen for the test (the forearm) can influence the results and could be different if using other areas, for example the back 5 ; 2) problems could also arise from using commercial products instead of purified substances, due to some possible irritating effects of preservatives. Only benzethonium chloride could modify the external validity of our results. In our study the maximum concentration of benzethonium chloride used in intradermal tests (0.02 mg/ml for 10 mg/ml ketamine) should provoke no skin reaction (Communication from proceedings of the scientific Committee on Cosmetic Products and Non-Food Products Intended for Consumers concerning Benzethonium Chloride, adopted by the sCCNFP, 26th Plenary Meeting, 9 December 2003) . The testing of commercial products has a practical importance because these substances are commonly used for diagnostic purposes.
Using serial dilutions rather than a single concentration would increase the diagnostic value of the skin testing 22, 25 . The maximum non-reactive concentration, when exceeded, is associated with the risk of false-positive reactions and is the highest concentration for which the RW/IW ratio is less than 2. According to the société Française d'Anésthesie et de Réanimation, a RW/IW ratio less than 2 is considered negative 7 . For the intradermal test the midazolam concentration recommended by current guidelines is 0.5 mg/ml 5,9 . In our study, for 0.5 mg/ml midazolam half of the subjects surpass positivity criteria if we account for the doubling of the injection wheal (RW/IW greater than or equal to 2) and a flare can be observed in the majority of subjects. In our opinion, at this concentration of 0.5 mg/ml, there are frequent false-positive reactions. Therefore, from our study, the maximum test concentration for midazolam should be 0.25 mg/ml.
There are no previously published validated nonreactive concentrations for the intradermal test to ketamine. There are reports of IgE-mediated reactions to ketamine 26 and an intradermal skin test has been used in one patient 27 . From our study the maximum intradermal test concentration for ketamine is 0.25 mg/ml.
In sharp contrast to what we observed for intradermal tests, when prick testing for both midazolam and ketamine, no test area modification appeared. For midazolam, published recommendations for prick testing propose a concentration of 5 mg/ml but there are teams who work with 1 mg/ml 8 . Ketamine 10 mg/ml solution did not result in positive tests in any of the subjects. There are some teams who have used ketamine solutions with concentration of 50 mg/ml without invoking false-positive results 8 .
In conclusion, using more clustered concentrations than those resulting from decimal dilutions, we have identified the highest concentrations of midazolam and ketamine that are not associated with a false positive reaction in non-allergic healthy volunteers. We consider that this information is important and hope to see further validation from other groups.
